Intermediate risk prostate cancer may be well controlled with brachytherapy alone


For men with intermediate risk prostate cancer, radiation treatment with brachytherapy alone can result in similar cancer control with fewer long-term side effects, according to research presented at the 58th Annual Meeting the American Society for Radiation Oncology (ASTRO).

The study is conducted at 68 cancer centers throughout the U.S. and Canada from 2003 to 2012 to assess whether brachytherapy conveyed an additional benefit or control of the cancer growth at five years following treatment.

Brachytherapy is a type of radiation therapy where radioactive seed implants are inserted directly into a patient’s tissue to deliver treatment to the tumor while limiting radiation exposure for surrounding tissue.

Participants in the study included 588 men diagnosed with intermediate risk prostate cancer and enrolled in the trial between 2003 and 2012.

Prostate cancer risk groups are assigned based on the prostate biopsy results and the prostate specific antigen (PSA) level in the patient’s blood at the time of diagnosis.